Slingshot members are tracking this corporate initiative:
Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications. TCB is responsible for development of all targets through Phase 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.Financial terms of the agreement include a $16 million upfront payment and subsequent potential R&D and commercial milestone payments. TCB is also eligible to receive undisclosed tiered royalties on product sales.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 07, 2017 Projected Implementation: Q4, 2017 Relevance Tracked Until: Q2, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords Car T-cell, Cancer Immunotherapy